The American pharmaceutical supply chain has become dangerously dependent on imports and foreign-controlled supply chains. Over the past 20 years, the country has experienced a skyrocketing rate on pharmaceutical imports and increasing foreign reliance.
A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
President Trump’s Executive Order is a bold, necessary move to rebuild America’s pharmaceutical industry and protect our citizens.
President Trump’s action to close the de minimis loophole for China is a monumental victory for American workers, manufacturers, and national security.
The IPO, widely seen as the first major test of President Trump’s America First Investment Policy (AFIP), directly undermines the President’s February directive to block U.S. investment in companies linked to the Chinese military, human rights abuses, and authoritarian surveillance state.
The American people, Congress, and the President have spoken. Now it’s Wall Street’s turn to decide.
Feeding America with abundant, healthy, locally-produced food is as important as any trade or industrial goal. Reinforcing our capacity to feed ourselves makes the nation stronger, safer, and more prosperous, whole the Big Ag status quo blindly follows a globalized model that has left far too many American farms behind.
The Department’s decision confirms what CPA has consistently warned: Chinese solar companies have been illegally circumventing U.S. trade laws through Southeast Asian shell operations, flooding the U.S. market with dumped and subsidized products directly harming the domestic solar manufacturing industry.
The Department of Defense designated CATL as a “Chinese military company” under Section 1260H of the National Defense Authorization Act on January 7. Their concern: CATL’s advanced lithium-ion batteries may one day be used to power China’s submarine fleet, replacing older battery models.
The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
